EGFR and non-small cell lung carcinoma: Precision therapies have dramatically improved progression free survival (PFS) and overall survival (OS) of NSCLC patients whose tumors harbor positive driver gene mutations, such as EGFR (19 Del and L858R) (2), rearranged ROS1 (3), or translocated ALK (4).